
Lucy Letby supporter claims neo-natal unit where baby serial killer worked was 'not fit for purpose'
The Countess of Chester Hospital's neo-natal unit was 'not fit for purpose' before Lucy Letby started murdering babies, a former nurse who worked there has claimed.
Michele Worden said redundancies led to a loss of senior staff and plumbing issues created a 'perfect storm' for care failings.
The former advanced nurse practitioner left the Countess after being made redundant in 2007, four years before Letby started working and eight years before her killing spree began.
She told the Nursing Times that when the unit was downgraded in around 2006 and stopped caring for very premature babies under 27 weeks, senior nurses were replaced with junior staff who were asked to care for infants 'above their capabilities [and] training.'
She said: 'It wasn't just the neonatal unit that wasn't fit for purpose, the whole maternity and paediatric and gynaecology… was not fit for purpose.
'The problems with the sewage and blocked sinks were not just [on] the neonatal unit, it was on the labour ward, it was all over.'
Ms Worden said she believed the situation at the Countess of Chester was 'no different' to other NHS hospitals where maternity scandals have been uncovered in recent years.
'Hopefully Lucy will be exonerated,' she said. 'Chester is no different than Shrewsbury, Nottingham, Morecambe Bay. Women and children's healthcare has never been a high priority.'
Letby, 38, is serving 15 whole life terms after being convicted of the murder of seven babies and attempted murder of seven more, including one baby girl she tried to kill twice.
Plumber Lorenzo Mansutti, estates manager at the Countess, was the only witness called by Letby in her defence at her Manchester Crown Court trial.
He admitted drainage problems were a 'weekly' issue at the hospital's 50-year-old Women's and Children's Building and told the jury that he remembered an incident when raw sewage backed up into sinks in the intensive care nursery.
But he said it was a 'one off' and insisted that at no point were staff unable to wash their hands because the hospital had 'backup' portable handwashing units on site. The problem was not logged as a formal incident, so no exact date for the incident could be found.
Letby's trial heard that none of the seven babies who died collapsed due to a bacterial infection associated with poor sewage.
Cheshire police are continuing to investigate the former nurse and last year confirmed they had questioned her in prison in connection with more baby deaths.
But, following a presentation from 14 international experts in February, who claim none of the babies were murdered but died due to poor care, there has been a continued chorus of people questioning the safety of her convictions.
Letby has twice applied and been refused leave to appeal, but her new legal team have submitted a file of evidence to the Criminal Cases Review Commission, the body that investigates potential miscarriages of justice, in a last ditch attempt to get her convictions overturned.
They claim the testimony of lead prosecution expert Dewi Evans was biased and that he changed his mind over the method of murder of one of the children murdered by Letby, a boy known as Baby C. Dr Evans has denied this and the Court of Appeal has already dismissed claims he was not suitably qualified or lacked independence.
Yesterday it emerged that Dr Evans, who has been subjected to intense trolling online from Letby supporters, had been involved in an online row with one of them - an anonymous statistician who Dr Evans accused of being motivated by a sexual attraction to Letby.
According to the statistician, Dr Evans wrote: 'You seem very intense, and it's not unusual for men to have the hots for pretty young blonde females. A nursing uniform is a turn-on for some by all accounts.
'I would suggest you need to get out more, find yourself an available pretty young blonde female, with/without nursing credentials. But one who doesn't go to work intent on murdering her patients.'
The statistician said it was 'absurd' to say he believed Letby was innocent because she was 'blonde and pretty' and insisted he had come to that view after reviewing the transcripts of the trial.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
35 minutes ago
- Daily Mail
Mounjaro has cured me of these three common life-limiting conditions. I'm healthier now at 60 than I was at 40...
Since mid-January, I've been hiding a secret drug habit. Once a week I sneak off and jab myself with a syringe I bought online. Aged 60, I am one of the fast-growing band of midlife women using 'skinny jabs' even though I'm not obese (I'm 5ft 7in tall, back then weighed 13st and I don't have diabetes.)


Daily Mail
35 minutes ago
- Daily Mail
The expert's guide to what microplastics do to your body - and 22 ways to minimise your risk
When Orlando Bloom, 48, was pictured having a £10,000, two-hour treatment to remove microplastics from his blood, it thrust the subject back into the spotlight. 'Microplastics are the tiny plastic particles that you often can't see, as they're less than five millimetres, but they're everywhere,' explains Dr Liza Osagie-Clouard, a former surgeon and now founder of Solice, a preventative healthcare clinic.


Sky News
36 minutes ago
- Sky News
New leukaemia treatment hailed as 'milestone' in cancer management
A combination of targeted drugs, offering a chemotherapy-free approach to leukaemia, have been hailed a "milestone" in cancer care by scientists following a groundbreaking UK trial. Potentially offering better outcomes for some patients as well as being more tolerable, it could reshape the way chronic lymphocytic leukaemia (CLL) - the most common form of leukaemia in adults - is treated. The Flair trial took place at 96 cancer centres across the UK. Researchers from Leeds wanted to assess whether two targeted cancer drugs could perform better than standard chemotherapy among patients with CLL. Some 786 people with previously untreated CLL were randomly assigned to receive standard chemotherapy; a single targeted drug, ibrutinib, or two targeted drugs taken together, ibrutinib and venetoclax, with treatment guided by personalised blood tests. Ibrutinib is a type of drug known as a cancer growth blocker. It works by stopping signals that cancer cells use to divide and grow. Venetoclax blocks the functions of a protein found in CLL cells. Researchers found that after five years, 94% of patients who received ibrutinib plus venetoclax were alive with no disease progression. That compared with 79% for those on ibrutinib alone and 58% for those on standard chemotherapy, according to the study, which has been published in the New England Journal of Medicine and presented to the European Haematology Association congress in Milan, Italy. Meanwhile 66% of patients on the new combination had no detectable cancer in their bone marrow after two years, compared with none of the people who received ibrutinib alone and 48% on chemotherapy. Experts said that the new treatment regime was also tolerated better than traditional treatments. 'An era of truly personalised medicine' Dr Talha Munir, consultant haematologist at Leeds Teaching Hospitals NHS Trust, who led the study said: "Flair trial is a milestone. "We have shown that a chemotherapy-free approach can be not only more effective but also more tolerable for patients. "By tailoring individualised treatment based on how well the cancer responds, we're moving into an era of truly personalised medicine." Catherine Whitfield, 63, from Farnley, West Yorkshire, was diagnosed with CLL in 2018 after she noticed symptoms including bleeding gums, constant illness and neck pain. She signed up to the trial, which was coordinated by the Leeds Cancer Research UK Clinical Trials Unit at the University of Leeds and sponsored by the University of Leeds. She said: "After three years of treatment, I am still MRD negative - that means no cancer cells. "I lost my husband to cancer. I have seen how hard it could be. "My first thought after my diagnosis was, I will never see my grandchildren being born and growing up. "Now I have two grandchildren, Drew and Alaia, and they are a delight and highlight the joys of a healthy life." 'Kinder, more targeted treatment' Ms Whitfield added: "The way this trial was explained, it just made sense. "Also, the thought of chemotherapy was scary to me. The trial felt right. And it was." Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, which funded the trial along with AbbVie, and Johnson and Johnson, said: "The results of the Flair trial show that we can provide kinder, more targeted treatment for chronic lymphocytic leukaemia, which gives people with CLL more precious time with their loved ones. "We're hopeful that the results of the Flair trial will power new treatment options for leukaemia and other blood cancers, thanks to the efforts of researchers in Leeds and across the UK working together on this trial." CLL is the most common form of leukaemia in adults, affecting the blood and bone marrow. While it cannot usually be cured, it can be managed with treatment.